Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.26 USD

39.26
1,211,621

+0.45 (1.16%)

Updated Nov 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Nektar (NKTR) Starts PROPEL Combo Study for Cancer Candidate

by Zacks Equity Research

Nektar (NKTR) initiates phase I/II combo study on lead candidate NKTR-214 along with Tecentriq and Keytruda. The trial complements Nektar's ongoing PIVOT research clubbed with Opdivo.

    Array's NDAs for Melanoma Combo Accepted for Review by FDA

    by Zacks Equity Research

    Array BioPharma's (ARRY) new drug applications for the combination of binimetinib and encorafenib to treat melanoma, accepted for review by the FDA.

      Novartis' BLA for Biosimilar of Rituxan Accepted by the FDA

      by Zacks Equity Research

      Novartis AG (NVS) announced that the FDA accepted its Biologics License Application for a proposed biosimilar version of Roche Holding AG's (RHHBY) Rituxan.

        Roche's Ophthalmology Drug Fails to Meet Primary Endpoint

        by Zacks Equity Research

        Roche's (RHHBY) share price declined after its ophthalmology candidate, lampalizumab, failed to meet the primary endpoint in phase III Spectri study.

          AbbVie Submits NDA for Endometriosis Candidate to the FDA

          by Zacks Equity Research

          AbbVie Inc. (ABBV) and partner Neurocrine Biosciences announced that the new drug application (NDA) for their pipeline candidate, elagolix, has been submitted to the FDA.

            MEI Pharma-Presage Biosciences on License Deal for Voruciclib

            by Zacks Equity Research

            MEI Pharma (MEIP) signs a license contract with Presage Biosciences to develop its CDK inhibitor, voruciclib, by dint of which, it nabs exclusive rights to the oncology candidate.

              4 Drug Stocks Worth a Look on Promising Cancer Pipeline

              by Zacks Equity Research

              Cancer is the second most common cause of death in the U.S. preceded only by heart disease. We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.

                Incyte (INCY) Reports Positive Data on Epacadostat/Keytruda

                by Zacks Equity Research

                Incyte Corporation (INCY) announced new and updated data from the ongoing phase I/II ECHO-202 trial on pipeline candidate epacadostat with Keytruda.

                  Parkinson's Now a Hot Therapeutic Area: What's Up Lately?

                  by Zacks Equity Research

                  Parkinson's disease is a lucrative area due to lack of curative therapy in this space. Many players are trying to bring new treatments to the market. A lot has happened in last couple of months.

                    Roche's (RHHBY) Actemra Gets FDA Nod for Label Expansion

                    by Zacks Equity Research

                    Roche Holding AG's (RHHBY) drug Actemra got FDA approval for label expansion.

                      Immunogen Inks Deal With Jazz Pharma to Develop ADC Molecule

                      by Zacks Equity Research

                      ImmunoGen (IMGN) and Jazz Pharma announced a strategic collaboration to develop and commercialize antibody-drug conjugate products.

                        AstraZeneca and Takeda Ink Deal to Develop Parkinson's Drug

                        by Zacks Equity Research

                        AstraZeneca (AZN) and Takeda Pharmaceutical Company entered into an agreement to jointly develop and commercialize MEDI1341 for the potential treatment of Parkinson's disease.

                          Merck's CETP Inhibitor Reduces Cardiovascular Risk by 9%

                          by Zacks Equity Research

                          Detailed results from Merck's (MRK) REVEAL study on anacetrapib, showed that the CETP inhibitor and a statin reduced the risk of major coronary events by 9% relative to placebo.

                            Roche's Gazyva Gets Priority Review for Follicular Lymphoma

                            by Zacks Equity Research

                            Roche Holding AG (RHHBY) announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review to leukaemia drug Gazyva.

                              Novartis Announces Positive Data on Cardiovascular Drug

                              by Zacks Equity Research

                              Novartis AG (NVS) announced positive primary data on pipeline candidate canakinumab (ACZ885).

                                Swarup Gupta headshot

                                Foreign Stock Roundup: WPP 1H17, BHP Billiton Fiscal 2017 Results Impress

                                by Swarup Gupta

                                Foreign markets remained focused on the outcome of the annual economic symposium at Jackson Hole last week.

                                  Sangamo Therapeutics Initiates Dosing in Hemophilia A Study

                                  by Zacks Equity Research

                                  Sangamo Therapeutics (SGMO) and partner Pfizer announced the dosing of first patient in Alta study on Hemophilia A candidate, SB-525.

                                    Novartis (NVS) Receives EC Approval for Breast Cancer Drug

                                    by Zacks Equity Research

                                    Novartis AG (NVS) obtained approval for its breast cancer drug Kisqali in Europe.

                                      Arpita Dutt headshot

                                      Pharma Stock Roundup: Roche Drug Gets Priority Review, EU Nod for Novartis Drug

                                      by Arpita Dutt

                                      It was a pretty slow week with key highlights including regulatory updates from companies like Roche (RHHBY) and Novartis.

                                        Celldex Ends Phase II Enrollment for Breast Cancer Candidate

                                        by Zacks Equity Research

                                        Celldex (CLDX) announces completion of enrollment in METRIC, a phase IIb study, evaluating glembatumumab vedotin for breast cancer treatment.

                                          Roche (RHHBY) Hemophilia A Drug Granted Priority Review

                                          by Zacks Equity Research

                                          Roche Holdings AG (RHHBY) announced that its Biologics License Application (BLA) for hemophilia A candidate, emicizumab has been accepted by the FDA and granted priority review.

                                            BioLineRx Moves a Regulatory Submission for BL-8040 Trial

                                            by Zacks Equity Research

                                            BioLineRx (BLRX) forwards a regulatory submission to begin a phase III study to evaluate BL-8040 in combination with G-CSF for treatment of multiple myeloma.

                                              Arpita Dutt headshot

                                              Biogen & 6 Other Multiple Sclerosis Drug Stocks in Focus: Here's Why

                                              by Arpita Dutt

                                              Late last week, Biogen (BIIB) and six other pharma and biotech stocks were in the news due to the pricing of their multiple sclerosis ("MS") drugs.

                                                Mylan Finalizes Settlement Agreement with DOJ for $465M

                                                by Zacks Equity Research

                                                Mylan N.V. (MYL) signed an agreement with the U.S. Department of Justice (DOJ) and two other relators to finalize the Medicaid drug rebate settlement worth $465 million, announced in Oct 2017.

                                                  Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx

                                                  by Zacks Equity Research

                                                  Exelixis, Inc. (EXEL) submitted its supplemental New Drug Application (sNDA) to the FDA for Cabometyx tablets for patients with previously untreated kidney cancer.